Clinical Metabolomics Inc

Xosomix LLC is a biotechnology company based in San Diego, CA, focused on developing next-generation therapeutics utilizing exosomes. With a unique approach to treating brain disorders, Xosomix aims to enhance the efficacy of current medications and support cellular repair through the innovative use of exosomal technology. Founded on groundbreaking preclinical research demonstrating the therapeutic potential of exosomes in conditions such as Rett Syndrome, Xosomix is positioned within the biotech incubator JLABS by Johnson & Johnson Innovation. The company is dedicated to addressing the significant unmet needs in the $100 billion brain disorder therapeutics market. Generated from the website

Cybele Microbiome Inc, based in San Diego, CA, is a pioneering company dedicated to enhancing skin health through a profound understanding of the microbiome. By recognizing the microbiome as a vital component in inflammation control, infection protection, and wound healing, Cybele aims to revolutionize skincare by transforming traditional approaches that have long viewed it as an adversary. The company focuses on the intricate relationship between skincare ingredients and microbiome health, conducting clinical trials to demonstrate the efficacy of their innovative formulations. With a commitment to achieving better results and fewer side effects, Cybele collaborates with top scientists to unlock the potential of postbiotics for real skin improvement. Generated from the website

Neuropore Therapies, Inc. is a San Diego-based biopharmaceutical company dedicated to discovering innovative therapeutics that target the underlying causes of neurodegenerative diseases, with the mission of halting their progression. Their current clinical trials include the Phase 2 study of UCB0599 in patients with early-stage Parkinson's disease, and they have recently received a substantial grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of their TLR2 program. With a team of experts and strategic partnerships with corporate foundations and academic institutions, Neuropore Therapies is well-positioned to make significant advancements in the field of neurodegenerative disease research. Their publications highlight the promising effects of their small molecule, NPT200-11, in a transgenic mouse model of Parkinson's disease, demonstrating their commitment to finding potential therapeutic solutions. Located in San Diego, California, Neuropore Therapies is dedicated to making a positive impact on the lives of individuals affected by neurodegenerative diseases.Generated from the website